Safety and Tolerability of Systemic Beta-2-Adrenergic AgonistAlbuterol as Pharmacological Therapy in Non-Invasive Ventilation NIV -supported Amyotrophic Lateral SclerosisALSPatients with Chronic Respiratory Failure (P4.079)

CONCLUSIONS:Systemic albuterol is 94.2% tolerable when used in NIV-supported ALS patients.M NIV-supported ALS patients more commonly required albuterol.VC was maintained at 3 months without change but not at 6 months in albuterol-treated NIV-supported ALS patients.Further studies are required on pharmacologically enhancing the treatment of NIV-supported ALS patients.Study Supported by:Carolinas ALS Research Fund/Pinstripes Fund/Carolinas Garden of Hope/Carolinas Healthcare FoundationDisclosure: Dr. Brooks has received personal compensation for activities with Biogen Idec, Avanir Pharmaceuticals, Acorda Therapeutics, Cytokinetics, Synapse, and the National Institute of Neurological Disorders and Stroke. Dr. Brooks has received research support from Biogen Idec, Avanir Pharmaceuticals, Cytokinetics, Neuraltus Pharmaceuticals, GlaxoSmithKline, Inc., and the National Institute of Neurological Disorders and Stroke. Dr. Kandinov has nothing to disclose. Dr. Langford has nothing to disclose. Dr. Lindblom has nothing to disclose. Dr. Sanjak has nothing to disclose. Dr. Wright has nothing to disclose. Dr. Ward has nothing to disclose. Dr. Holsten has nothing to disclose. Dr. Fischer has nothing to disclose. Dr. Lucas has nothing to disclose. Dr. Smith has nothing to disclose. Dr. Nichols has nothing to disclose. Dr. Lary has nothing to disclose. Dr. Nemeth has nothing to disclose. Dr. Russo has received personal compensation for activities with Teva Neuroscience and Biogen Idec as a c...
Source: Neurology - Category: Neurology Authors: Tags: ALS: Trials and Biomarkers Source Type: research